Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodevelopmental and Psychiatric Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SHANK3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SHANK3 Recombinant Domain Proteins (PDZ, SH3, SAM domains) High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for PPI screening. |
View SHANK3 Products |
| Gene Delivery | SHANK3 Promise-ORF / Lentivirus Full-length ORF and specific clinical mutant constructs for stable neuronal cell line generation. |
View SHANK3 Products |
| Benchmark Ab | Anti-SHANK3 Recombinant Antibody High-affinity positive control clone validated for Western Blot, Immunofluorescence, and IP assays. |
View SHANK3 Products |
| Validator | SHANK3 siRNA Set Target-specific knockdown pool for functional verification in primary neurons or iPSC models. |
View SHANK3 Products |
| Related Target A | NLGN3 Neuroligin-3; key trans-synaptic adhesion partner upstream of the SHANK scaffold complex. |
View NLGN3 Products |
| Related Target B | NRXN1 Neurexin-1; presynaptic organizer bridging synaptic networks to downstream SHANK3 complexes. |
View NRXN1 Products |
| Related Target C | GRIN2B NMDAR Subunit 2B; critical downstream channel receptor anchored by PSD-95/SHANK3 networks. |
View GRIN2B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstitution of Postsynaptic Density (PSD) Complexes | High-purity, sequence-verified isolated domain proteins (SH3, PDZ, SAM) to map precise PPIs. |
| Isoform and Mutation-Specific Modeling | Custom Lentiviral vectors containing patient-derived microdeletions or point mutations (e.g., InsG). |
| Lack of Reliable Intracellular Controls | Highly validated recombinant screening antibodies for spatial localization and expression monitoring. |
| Off-Target Scaffold Signaling Effects | Homolog panel screening reagents (SHANK1, SHANK2) to guarantee target-specific therapeutic profiles. |
Live SHANK3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SHANK3 therapeutics is intensifying, with major players shifting focus from traditional symptomatic neuropharmacology to genetic medicine and precision modulation of synaptic scaffolding. As first-generation therapies reach the clinic, the next wave of R&D is targeting gene-dosage restoration, small-molecule protein-protein interaction (PPI) stabilizers, and downstream receptor channel modulators.
Because SHANK3 is a master scaffolding protein within the postsynaptic density (PSD), complete deletion or mutation leads to severe synaptic dysfunction, clinically manifested as Phelan-McDermid Syndrome (PMS) and monogenic Autism Spectrum Disorders (ASD). Current clinical strategies focus on AAV-mediated gene replacement, antisense oligonucleotides (ASOs) to enhance endogenous translation, and small molecules designed to stabilize downstream signaling components such as NMDAR and AMPAR networks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Jaguar Gene Therapy, Novartis | Phelan-McDermid Syndrome (PMS) | Expression and localization validation (Need SHANK3 Lentivirus & Specific Abs) |
| ASO / RNA Therapeutics | Servier, Academic Consortia | Autism Spectrum Disorder (ASD) | Endogenous upregulation screening (Need target-specific siRNA controls & qPCR primers) |
| Small Molecule (PPI Stabilizers) | Neuren Pharmaceuticals, Acadia | Rett-like / SHANK3-deficient Synaptopathies | In vitro binding assays (Need high-purity recombinant PDZ/SAM domains) |